FYN-MEDIATED PHOSPHORYLATION OF NR2B TYR-1336 CONTROLS CALPAIN-MEDIATED NR2B CLEAVAGE IN NEURON AND HETEROLOGOUS SYSTEMS

Hai-Yan Wu¹, Fu-Chun Hsu³, Amy J. Gleichman¹,², Isabelle Baeconguis¹, Douglas A. Coulter¹,² and David R. Lynch¹,²*

Departments of Pediatrics and Neurology,¹ Children’s Hospital of Philadelphia and ²University of Pennsylvania, Philadelphia, Pennsylvania, 19104

Running Title: Fyn, calpain and NR2B

Address Correspondence to: Dr. David R. Lynch, Division of Neurology, Children’s Hospital of Philadelphia, 502 Abramson Building, Philadelphia, Pennsylvania 19104-4318, Tel. 215-590-2242; Fax. 215-590-3779; E-Mail: lynch@pharm.med.upenn.edu

Cleavage of the intracellular carboxy-terminus of the NMDA receptor 2 subunit (NR2) by calpain regulates NMDA receptor function and localization. Here, we show that Fyn-mediated phosphorylation of NR2B controls calpain-mediated NR2B cleavage. In cultured neurons, calpain-mediated NR2B cleavage is significantly attenuated by blocking NR2B phosphorylation of tyrosine (Y) 1336, but not Y1472, via inhibition of Src family kinase activity or decreasing Fyn levels by siRNA. In HEK cells, mutation of Y1336 eliminates the potentiating effect of Fyn on calpain-mediated NR2B cleavage. The potentiation of NR2B cleavage by Fyn is limited to cell surface receptors and is associated with calpain translocation to plasma membranes during NMDA receptor activation. Finally, reducing full length NR2B by calpain does not decrease extrasynaptic NMDA receptor function, and truncated NR1/2B receptors similar to those generated by calpain have electrophysiological properties matching those of wild-type receptors. Thus, the Fyn-controlled regulation of NMDA receptor cleavage by calpain may play critical roles in controlling NMDA receptor properties during synaptic plasticity and excitotoxicity.

Keywords: Calpain, NMDA receptor, Fyn kinase, proteolysis, phosphorylation

The N-methyl-D-aspartate (NMDA) receptor is a calcium permeable ionotropic glutamate receptor requiring glutamate, glycine, and membrane depolarization for activation. These receptors play crucial roles in brain development, excitatory neurotransmission, and synaptic plasticity, but also may contribute to the pathogenesis of neurological disorders including ischemia, epilepsy, and Huntington’s disease (1-4). NMDA receptors are made from heteromeric assemblies of different subunits called NR1 and NR2 (NR2A-D) (5-8). The NR2B subunit is essential for both neonatal and mature NMDA receptors and is highly expressed in the entire embryonic brain and the adult forebrain (9). In the hippocampus, the major neonatal receptor is believed to contain 2 NR1 and 2 NR2B subunits, while the major receptor in more mature synapses likely contains 2 NR1 subunits, an NR2A subunit and an NR2B subunit. Analysis of NR2B-null mice has suggested the physiological importance of NR2B, as absence of NR2B-containing NMDA receptors in NR2B⁻/⁻ mice leads to perinatal death, whereas mice lacking NR2A, NR2C and NR2D subtypes are viable (10-12).

NR2B subunits have long C-terminal tails that link NR2B to intracellular pathways. Like NR2B-deficient, mice expressing NR2B subunits with truncated C-terminal domains die shortly after birth (13), showing the physiological importance of the intracellular region of NR2B. Therefore, processes that modify the C-terminal region of NR2B may alter the physiological events mediated by NR2B-containing receptors. Calpain and tyrosine kinases regulate NMDA receptors through the C-terminal domain. Calpain, a Ca²⁺-dependent neutral cysteine protease, cleaves the C-terminal domain of NR2B in
HEK cells, neuronal cultures and animal models of ischemia and seizures (14-17). In acutely isolated and cultured cortical neurons, prolonged stimulation of NMDA receptors reduces NMDA receptor-mediated currents in a manner requiring calpain activation (18). In cultures of hippocampal neurons, calpain-mediated cleavage of NR2B produces truncated receptors that remain on the cell surface but potentially have novel properties (16,19). These studies indicate that calpain-mediated truncation of NR2B may regulate NMDA receptor function and localization.

The NR2B subunit is tyrosine phosphorylated in neurons (20-22). Fyn, a Src family tyrosine kinase, phosphorylates tyrosines 1252 (Y1252), Y1336 and Y1472 in the C-terminal domain of NR2B subunit in vitro, with Y1336 and Y1472 being the most readily phosphorylated sites in cell culture systems (23). A previous study limited to in vitro experiments suggested that Fyn and Src might regulate cleavage of NR2 subunits in opposing manners. Here, using in situ approaches in transfected cells and neurons, we have used molecular biological, physiological and receptor trafficking approaches to show that phosphorylation of tyrosine residue Y1336 by Fyn controls calpain-mediated proteolysis of NR2B without revealing any evidence for involvement of Src in situ. In addition the effects of Fyn are modulated in a novel way by NMDA receptor activation. This provides a novel mechanism through which Fyn regulates the NMDA receptor as part of a feedback loop.

**EXPERIMENTAL PROCEDURES**

**Materials:** Glutamate and glycine were obtained from Sigma-Aldrich (St. Louis, MO, USA); dizocilpine (MK-801) was obtained from Research Biochemicals International (Natick, MA, USA). Z-Val-Phe-CHO (MDL 28170; Calpain Inhibitor III (CalI3), calpain I and 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2) were purchased from Calbiochem (San Diego, CA, USA). Anti-NR2B antibody (made to the N-terminal 251 amino acids) was obtained from Zymed (San Francisco, California, USA). AB38, which recognizes calpain-cleaved spectrin, was produced as described previously (16). Anti-NR1 and anti-PSD-95 monoclonal antibodies were obtained from BD Transduction Laboratories (Lexington, KY, USA). Anti-actin antibody and antibody to NR2B phospho-Y1472 were obtained from Sigma-Aldrich (St. Louis, MO, USA). Anti-calpain I antibody was obtained from Chemicon (Temecula, CA, USA). Anti-Fyn antibody, anti-Src antibody, and antibody to NR2B phospho-Y1336, as well as pKD-Fyn-v6 and pKD-NegCon-v1 were obtained from Upstate (Lake Placid, NY, USA).

The following full-length cDNA constructs were gifts: Fyn Y531F from Dr. Tohru Tezuka (University of Tokyo, Tokyo, Japan); synapse-associated protein 102 (SAP-102) from Dr. Richard L. Huganir (Johns Hopkins University, Baltimore, MD); PSD-95 from Dr. David S. Bredt (University of California, San Francisco, CA); SrcY527F from Dr. Michael W. Salter (University of Toronto, Toronto, Ontario, Canada)

**Site-directed Mutagenesis of NR2B:** A PCR-based site-directed mutagenesis method was employed to generate the single amino acid mutants NR2BY1336F and NR2BY1472F. Wild-type NR2B in pRK7 was used as a template, and PCR was carried out for each mutant with a set of sense and anti-sense mutagenic primers (using the Stratagene Quik-Change kit). PCR products were treated with DpnI restriction enzyme and purified by agarose gel electrophoresis. Purified DNA was used to transform E. coli (DH5α), and transformants harboring mutant constructs were identified. Mutations were confirmed by DNA sequencing in the Molecular Biology Core of the Mental Retardation Research Center of the Children's Hospital of Philadelphia. Truncated NR2B (designated NR2Bdel1036) was constructed using PCR by replacing the CellI fragment (bases 3102 – 4116) with a modified corresponding fragment in which the 5′ end contained two stop codons at base 3109 (amino acid 1037). NR2B in pRK7 was primed with 5′-AACACAGCCAGCTCAGCTAGTAGTACG GCAAGTTCTCTTTC-3′ and 5′-GTCAG
GGTAGAGGGACTTGAGCATGTAGC
CGCTGCC -3' to create this construct.

Small Interfering RNA (siRNA)
Preparation and Transfection: A siRNA plasmid, pKD-Fyn-v6, specific for Fyn protein silencing, and a negative control plasmid for the siRNA, pKD-NegCon-v1, were amplified in DH5α cells and purified. HEK293 cells were transfected using calcium phosphate, and neurons were transfected via siIMPORTER™ transfection reagent (Upstate, Lake Placid, NY, USA) according to the manufacturer’s instruction. We transfected 10-11 DIV neurons in 12 well plates with the final concentration of 500 ng of corresponding siRNA plasmid (pKD-Fyn-v6 or pKD-NegCon-v1), and Fyn protein expression was assessed 96hrs after transfection (15-16 DIV) by immunoblotting. The species of the target for pKD-Fyn-V6 is human, but pKD-Fyn-V6 has a ~95% sequence homology to Rat Fyn and has no homology to other known rodent genes (based on BLAST searches).

In vitro Phosphorylation and Proteolysis of NR2B by Purified Calpain I: Twenty-four hours after transfection, HEK293 cells were rinsed with phosphate-buffered saline (PBS) and then scraped into phosphorylation buffer (200 mM Tris-HCl, 10mM MgCl₂, 5 mM MnCl₂, 0.4 µM Na₃VO₄, 500 µM ATP, 0.8 mM EGTA). Samples were briefly sonicated on ice, incubated at 56°C for 30 min to inactivate endogenous kinases and phosphatases, and then incubated with recombinant active Fyn protein (100 ng/ml) for 40 min at 30°C. After phosphorylation, samples were incubated with 2 unit/ml calpain I (Calbiochem) for 2 min at 30°C in a buffer containing final concentrations of 1 mM CaCl₂, 5 mM dithiothreitol, and 40 mM HEPES, pH 7.2. The reaction was stopped by an addition of SDS sample buffer, and the reaction mixtures were then loaded on an 8% SDS-PAGE gel.

Whole-cell Recording: Experiments were performed with standard whole-cell voltage-clamp techniques using transfected HEK293 cells 12-24 hrs after transfection and rat embryonic hippocampal neurons maintained in culture for 17-21 days DIV. NMDA-evoked currents were recorded at room temperature using NMDA (100 μM) along with glycine (10 μM) in a Mg²⁺-free extracellular recording medium containing 500 mM tetrodotoxin, 155 mM NaCl, 3 mM KCl, 3 mM CaCl₂ and 10 mM HEPES with pH value of 7.35. To examine NMDA receptor function, cells were voltage-clamped at -50 mV using an intrapipette solution containing (in mM) Trizma phosphate (dibasic) 100, Trizma base 28, EGTA 11, MgCl₂ 2, CaCl₂ 0.5 and Mg-ATP 10, pH 7.35, 290 mOsm/kg H₂O. Each application was 2 sec, and the interval between applications was more than 1 min to prevent current desensitization. Solution switching was carried out using a SF-77B fast-step solution delivery device (Warner Instrument Co., Hamden, CT). Recording signals were amplified using an Axopatch-1D amplifier, filtered at 5 kHz, then saved using an IBM PC running pCLAMP 8.01 software (Axon Instruments, Inc. Foster City, CA) for off-line analysis. NMDA, glutamate, and calpain inhibitor III (CalI3) were dissolved in extracellular solution. Some aliquots of CalI3 were solubilized in DMSO; final DMSO concentration was 0.001% (v/v). This concentration had no effect of whole-cell NMDA currents (data not shown). In order to observe the extrasynaptic NMDA receptor-mediated effects, synaptic NMDA receptors in hippocampal culture neurons were blocked with 50 μM bicuculline and 10 μM MK801 for 10 min. In addition, ifenprodil (10 μM) was used to confirm that NMDA receptor-mediated current in bicuculline/MK801 pre-treated neurons was primarily from extrasynaptic NMDA receptor (since they contain primarily NR1/2B). To examine the pharmacological effect of ifenprodil on NMDA receptors, ifenprodil was pre-administrated to the recorded neurons alone for more than 30 sec before neurons were co-applied with NMDA/Glycine and ifenprodil. Since the effect of ifenprodil could not be washed away within 30 min (data not shown), therefore, only one neuron per culture dish was recorded during these experiments.

Neuronal Cultures: Primary cultures of hippocampal and cortical neurons from
E17-19 Sprague Dawley rats (Charles River Laboratories, Wilmington, MA, USA) were prepared as described previously (16,24). Briefly, the hippocampi were dissected, gently minced, trypsinized (0.027%, 37°C; 7% CO2 for 20 min), and then washed with 1× HBSS. Neurons were seeded to a density of $6 \times 10^5$ viable cells per 35 mm culture dish or similar relative density onto 12 well plates or 60 mm culture dishes. All plates and culture dishes were coated with poly-D-lysine (100 µg/ml) prior to seeding neurons. Cultures were maintained at 37°C with 5% CO2, fed with neurobasal media with B27 supplement, and the cultures were used at 17-21 DIV.

**Western Blotting Analysis:** Western blotting was performed as described previously (16,24). Protein content was estimated using BCA Protein Assay (Pierce Chemical Co. USA). Equal amounts of total protein (15-20 µg per lane) were resolved on denaturing 8-10% SDS-PAGE gels, and transferred to nitrocellulose membranes. Membranes were blocked with 3% non-fat milk, and incubated with primary antibody for 2 hours at room temperature or overnight at 4°C. Blots were then incubated with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (Sigma-Aldrich, St. Louis, MO, USA) for 2 hours at room temperature, then washed; bands were visualized using enhanced chemiluminescence (ECL, Pierce, Rockford, IL, USA). Reaction product levels were quantified by scanning densitometry using NIH Image 1.62 (http://rsb.info.nih.gov/nih-image).

**Transfection of HEK293 Cells:** HEK293 cells were grown on tissue culture dishes in minimum Eagle's medium containing 5% horse serum, 5% fetal bovine serum supplemented with 2 mM glutamine, 100 units/ml penicillin/streptomycin and placed in a 5% CO2 incubator at 37°C. Transfection was performed using calcium phosphate as previously described (25). Treatments were performed 18-24 hours following transfection. Ketamine (500 µM) was included in the media during transfection to prevent NMDA receptor activation as previously described (25).

**Calcium Imaging:** HEK293 cells were cotransfected with NR1, SAP-102, and GFP with NR2B wild-type, NR2BY1336F, NR2BY1472F or NR2Bdel1036 (NR2B truncated at amino acid 1036) each with or without FynY531F. Eighteen to twenty hours later, transfected cells were identified via GFP fluorescence and selected for measurement of intracellular calcium responses. After loading with 5 µM fura-2–acetoxymethyl ester (Molecular Probes) for 30 min, cells were washed with HBSS twice. Intracellular calcium was measured by a dual-excitation wavelength method (340/380 nm) using a Nikon microscope in conjunction with Metafluor imaging software (Universal Imaging, West Chester, PA) (26).

**Biotinylation Assays:** Surface biotinylation was used to assess receptor expression on the cell surface. HEK 293 cells, grown in 60 mm dishes, were transfected with various cDNA combinations. Twenty-four hours after transfection, cell surface proteins were labeled with biotin and isolated (16). Cells were washed twice with cold rinsing solution (PBS Ca/Mg: 1 mM MgCl2, and 0.1 mM CaCl2, pH 7.35) (27) and incubated in rinsing solution containing 1 mg/ml EZ-Link Sulfo-NHS-Biotin (Pierce Chemicals, Rockford, IL) for 30 min at 4°C. Cells were washed twice with quenching solution (rinsing solution with 100 mM glycine added), incubated in quenching solution for 20 min, and solubilized at 4°C in RIPA buffer (150 mM NaCl, 1 mM EDTA, and 100 mM Tris HCl, pH 7.4; 1% (v/v) Triton X-100, 1% (w/v) deoxycholate, 0.1% (w/v) SDS containing protease inhibitors (1 µg/ml leupeptin, 250 µM PMSF, 1 µg/ml aprotinin, 1 mg/ml trypsin inhibitor, and 1 mM iodoacetamide). Samples were cleared by centrifugation at 16300 g at 4°C for 20 min. A small sample of cleared lysates was saved for analysis (designated the lysate fraction); the remaining portion of lysates was incubated with avidin beads (Pierce Chemicals) at 4°C overnight. After overnight incubation, samples were centrifuged at 16300 g for 15 min, and the supernatant was saved as the intracellular fraction. The beads were washed once in RIPA buffer, twice in cold high-salt...
buffer (0.1% Triton X-100, 500 mM NaCl, 5 mM EDTA, 50 mM Tris, pH 7.5), and once in low-salt buffer (50 mM NaCl, pH 7.5), and biotinylated proteins were eluted with SDS sample buffer (62.5 mM Tris-Cl, pH 6.8, 2% SDS, and 100 mM mercaptoethanol) at 37°C for 30 min. The remainder of the procedure followed standard Western blotting protocols. To confirm that biotin only labeled surface proteins, the integrity of the cell membrane during biotinylation was tested by immunoblotting with an anti-actin antibody. Actin immunoreactivity in the biotinylated fraction was 9 ± 2% (n = 24) of that in the whole cell lysate.

In selected experiments, biotinylations were performed under non-denaturing conditions by solubilizing cell membranes in RIPA buffer (lysis buffer) lacking SDS. Without SDS in the RIPA buffer, integral membrane proteins exposed to the extracellular space and thus labeled by biotin are not dissociated from membrane associated proteins bound to such integral membrane proteins by non-covalent interactions. This allows us to possibly detect the changes in association of non-integral membrane proteins (such as calpain) with biotinylated, cell surface exposed proteins in different experimental conditions.

**Statistical Analysis:** Data are shown as the mean ± S.E.M. Experiments were analyzed using Student’s t-test (paired) to compare two conditions or ANOVA followed by planned comparisons of multiple conditions (28). For most comparisons, non-normalized OD values were used. Significance was set at P < 0.05. All electrophysiology data, such as current amplitude, current desensitization and time constant (fitted with a single exponential component function using the Levenberg-Marquardt nonlinear least-squares algorithm), were calculated using Clampfit software (pCLAMP 8.01, Axon Instruments, Inc. Foster City, CA). We have designated “n” to refer to independent experiments in biochemical study, and independent single cells in electrophysiological studies.
**NR2B is Phosphorylated at Tyrosine 1336 During NMDA Receptor Activation in Neurons** - NR2B can be phosphorylated at tyrosine residues 1336 and 1472 (Y1336, Y1472) by Fyn, an SFK directly implicated in tyrosine phosphorylation of NMDA receptors in the brain (23,34). Since Fyn may change NR2 cleavage by calpain in vitro (35), we first tested whether Fyn mediated phosphorylation of NR2B at Y1336, Y1472, or both sites during NMDA receptor activation. Cultures were treated with glutamate and glycine, and the time course of Y1336 and Y1472 phosphorylation was determined using NR2B phospho-specific anti-Y1336 or anti-Y1472 antibodies (Fig. 2A and B). Levels of phosphorylation of Y1472 were similar over the period of 30 min glutamate stimulation (Fig. 2A). However, increased phosphorylation of Y1336 was noted rapidly (by 7.5 min after NMDA receptor activation) and increased 2.2-fold by 30 min (0 min, 100 ± 2%; 7.5 min, 151 ± 22%, 30 min, 219± 14%, p = 0.0095 at 7.5 min and p = 0.0004 at 30 min both vs 0 min, n = 5 each, Fig. 2B). The progressive phosphorylation of NR2B at Y1336 was associated with a gradual reduction of full length NR2B and generation of the NR2B breakdown product (Fig. 2C, D). Thus, while the level of full length NR2B declined with NMDA receptor activation, the immunoreactivity of phospho-Y1336-NR2B increased. In addition, phosphorylation of Y1336 in this condition is mediated by SFK, as PP2 (10 µM) eliminated phospho-Y1336 immunoreactivity at all indicated time points (Fig. 2A, B). Furthermore, PP2 slowed both the reduction of full-length NR2B and the generation of NR2B-derived breakdown products over a time course that generally resembled that for phosphorylation of NR2B-Y1336 (Fig. 2A, C, D). As in our previous work (16,19), inclusion of a calpain inhibitor decreased NR2B breakdown (data not shown) but increased the amount of Y1336 phosphorylation (Glu, 190 ± 7%; CalII+Glu, 330 ± 18%; n = 6, p = 0.0016 vs Glu. Fig. 2E), suggesting that NR2B-Y1336 is a substrate for calpain. MK-801 also blocked Y1336 phosphorylation (contr., 100 ± 6%; MK801+Glu. 94 ± 8%, n = 6, p = 0.57 vs contr., Fig. 2E). These results indicate that SFK-mediated phosphorylation and calpain-mediated proteolysis, which both regulate NR2B through the C-terminus, are facilitated by NMDA receptor activation in neurons. Since SFK inhibition decreases calpain-mediated NR2B cleavage, this also suggests that SFK-mediated phosphorylation of NR2B directly accelerates the calpain-generated NR2B breakdown.

**Fyn Accelerates Calpain-mediated NR2B Cleavage in Neurons** - To assess whether calpain-mediated NR2B cleavage during NMDA receptor activation in neurons is controlled by Fyn, we decreased endogenous Fyn protein expression using a small interfering RNA (siRNA) against Fyn coded in a DNA-based vector (36). The Fyn siRNA, which has no homology to other known rodent genes (based on BLAST searches of the sequences), decreased endogenous Fyn protein in HEK293 cells and in cultured hippocampal neurons to 30–35% of levels detected in mock expression 96 hours after transfection (Fig. 3A, B). As noticed by protein levels of actin (data not shown), spectrin breakdown (frequently an early marker of cell death) and the NR1 NMDA receptor subunit (Fig. 3D) from untransfected and transfected neurons, siRNA transfection did not produce any significant neuronal toxicity in our culture paradigm. The levels of Src protein were not affected (data not shown). At this time point, Fyn knockdown substantially diminished phosphorylation of NR2B-Y1336 (Fig. 3C) and protected NR2B from calpain-mediated proteolysis after NMDA receptor activation (Fig. 3D). After a 30 min treatment of 100 µM glutamate and 100 µM glycine, full length NR2B decreased 20% in neurons transfected with Fyn siRNA, 45% in untransfected neurons, and 44% in neurons transfected with a mock construct (Fig. 3D, E; Untransfected neurons, Contr., 100 ± 6%; Glu., 55 ± 0.3%; siRNA, Contr., 100 ± 11%, Glu., 81.0 ± 1%; Mock, Contr. 100 ± 0.4%, Glu., 56 ± 12%, n =5 each). Fyn siRNA-transfected neurons also generated lower levels of the NR2B-derived breakdown product (Fig. D, F; Untransfected neurons, Contr., 11 ± 1%; Glu., 73 ± 5%);
siRNA, Contr., 12 ± 1%, Glu., 33 ± 4%; Mock, Contr. 10 ± 0.3%, Glu., 69 ± 5%, n = 5 each). Transfection of the control siRNA construct (mock) did not alter NR2B breakdown. In each transfection, calpain-mediated cleavage of spectrin was similar after agonist treatment for 30 min (Untransfected neuron, Contr., 100 ± 6%; Glu., 560 ± 80%; siRNA, Contr., 100 ± 6%; Glu., 570 ± 60%; mock, Contr. 100 ± 13%, Glu., 540 ± 60%, n = 5 each, data not shown). Thus, decreasing Fyn protein expression by siRNA decreases calpain-mediated proteolysis of NR2B in neurons, but does not alter calpain-mediated cleavage of other substrates.

Facilitation of Calpain-mediated NR2B Cleavage by Fyn-mediated Phosphorylation of NR2B-Y1336 in HEK 293 Cells - To determine whether calpain-mediated NR2B cleavage is controlled selectively by Fyn-mediated phosphorylation, we investigated the effects of Fyn on cleavage of NR2B in HEK cells. We transfected HEK cells with an expression plasmid encoding FynY531F, a constitutively active form of Fyn, along with cDNAs for NR1, NR2A, and NR2B. NR2A expression is needed for calpain-dependent activation in HEK cells (24). The membrane-associated guanylate kinase (MAGUK) protein PSD-95 promotes Fyn-mediated phosphorylation of NR2B in vitro (23), but also protects NR2B from cleavage by calpain (24). We expressed NMDA receptor subunits with PSD-95 or with synapse-associated protein 102 (SAP-102), a MAGUK protein similar to PSD-95 that binds to NR2 subunits but does not alter cleavage of NR2B by calpain (24). In agreement with others (23), recombinant NR2B could be phosphorylated by FynY531F at Y1336 when NR2B was cotransfected with PSD-95 (Fig. 4A last lane). Phospho-Y1336 was also detected in cells transfected with NR1/2A/2B/FynY531F and SAP-102 (Fig. 4A middle lane). Replacing PSD-95 or SAP-102 with an empty vector control led to no detectable phosphorylation of NR2B-Y1336 (Fig. 4A first lane), suggesting that PSD-95 or SAP-102 is needed for Fyn-mediated phosphorylation of NR2B-Y1336 (Fig. 4A).

We next studied whether Fyn-mediated phosphorylation of NR2B at Y1336 altered calpain-mediated cleavage of NR2B in this system. Following 100 µM glutamate and 100 µM glycine application, full length NR2B immunoreactivity decreased by 29% in cells transfected with NR1/2A/2B/SAP-102/vector compared to those cells without agonist stimulation (Contr., 100 ± 5%, Glu., 71 ± 1%, p = 0.0042 vs Contr., n = 6 each, Fig. 4B, C), while full length NR2B immunoreactivity in cells expressing NR1/2A/2B/SAP-102/FynY531F decreased by 62% (Contr., 100 ± 3%, Glu., 38 ± 2%, p = 0.0001 vs Contr., n = 6 each, Fig. 4B, C). The decreases in NR2B immunoreactivity in both transfected conditions were completely blocked by 10 µM calpain inhibitor III (CalI3+Glu, 103 ± 4% in cells without FynY531F, p = 0.65 vs Contr.; 95 ± 2% in cells with FynY531F, p = 0.24 vs Contr., n = 6 each, Fig. 4B, C). The facilitation of calpain-mediated NR2B cleavage by FynY531F was selective for NR2B, as actin (Fig. 4B) and NR1 (data not shown) were unaltered by FynY531F, and calpain-generated spectrin breakdown increased to similar levels in cells with and without FynY531F application (increase 650 ± 20% in cells without FynY531F; increase 670 ± 35% in cells with FynY531F, n = 6, Fig. 4B, E). Thus, in this heterologous system, FynY531F does not globally increase calpain activity but selectively facilitates calpain-mediated cleavage of NR2B. In addition, as observed in neuronal cultures, we detected increased levels of Y1336 phosphorylation in cells cotransfected with FynY531F (Immunoreactivity, Contr., 9500 ± 470; Glu., 11500 ± 480; CalI3+Glu., 36100 ± 2070; n = 6, p = 0.04 vs Contr., Fig. 4B, D), further demonstrating that the increase in the immunoreactivity of NR2B phospho-Y1336 and the reduction of the level of NR2B both occurred after NMDA receptor activation. Pre-application of calpain inhibitor III substantially augmented the level of NR2B phosphorylation at Y1336 at 30 min after glutamate and glycine application (p = 0.0003 vs Glu, Fig. 4B, D), but had no effect without agonist treatment (data not shown). This further suggests that calpain preferentially cleaves Fyn phosphorylated NR2B subunits.
The Effect of PSD-95 on Fyn-mediated Facilitation of NR2B Cleavage in HEK Cells - We previously found that PSD-95 protects NR2B from calpain-mediated proteolysis during NMDA receptor activation (24). To examine whether Fyn-mediated phosphorylation of NR2B alters the protection of NR2B from calpain-mediated cleavage by PSD-95, HEK cells cotransfected with NR1/2A/2B/FynY531F and either PSD-95 or vector control were incubated with NMDA receptor agonists and analyzed by western blots using anti-N-terminal NR2B, anti-phospho-NR2B-Y1336 and AB38. Immunoreactivity of phospho-Y1336 of NR2B was detected at baseline, and increased with the application of NMDA receptor agonists for 30 min (Contr., 100 ± 4%; Glu., 196 ± 17%; n = 5, p = 0.016 vs Contr., Fig. 5A) In contrast to results from SAP-102 cotransfected cells (Fig. 4B, D), 100 µM glutamate and 100 µM glycine applications did not significantly decrease the immunoreactivity of full length NR2B (Contr., 100 ± 1%; Glu., 85± 8%, n = 5, p = 0.10 vs Contr., Fig. 5B), whereas increased levels of spectrin breakdown by calpain were detected 30 min after agonist application and were inhibited by pre-application of calpain inhibitor III (Contr., 100 ± 12%; Glu., 370 ± 16%; p = 0.0035 vs Contr., CalI3+Glu., 130 ± 8%, p = 0.14 vs Contr., n = 5 each; Fig. 5C). Pre-application of calpain inhibitor III did not further increase the phosphorylation of NR2B-Y1336 (CalI3+Glu, 205 ± 9%, p = 0.0046 vs Contr., p = 0.57 vs Glu. n = 5 each, Fig. 5A), suggesting that even Y1336 phosphorylated NR2B is not readily degraded by calpain in this paradigm. These results indicate that PSD-95 protects NR2B from calpain-mediated cleavage in NMDA receptor transfected HEK cells consistent with our previous finding (24), and phosphorylation of NR2B at Y1336 by FynY531F did not remove the ability of PSD-95 to block calpain-mediated cleavage of NR2B.

Because another SFK, Src, changes calpain-mediated cleavage of NR2A in vitro (35), we examined whether Src kinase can alter calpain-mediated cleavage of NR2B and phosphorylation of NR2B-Y1336. Constitutively active Src (SrcCA) (SrcY527F) or a vector control was expressed in HEK cells with NR1/2A/NR2B/SAP-102 (Fig.5D). Compared with the corresponding 0 min control, 30 min application of glutamate and glycine reduced the NR2B immunoreactivity to 70% of control levels (n=5; p=0.011) in cells transfected with SrcCA and to 72% (n=5; p=0.019) in cells transfected with a vector control. Calpain-generated spectrin breakdown increased to the same extent at 30 min after agonist application in both transfected conditions (Fig. 5D). Both the reduction of NR2B levels and the increase in spectrin breakdown were completely blocked by pre-treatment with calpain inhibitor III (data not shown). The immunoreactivity of actin did not change before or after agonist application in any transfected condition (Fig. 5D). In addition, immunoreactivity of phosphorylated NR2B-Y1336 was undetectable before or after agonist treatment in cells either with or without SrcCA coexpression, showing that NR2B-Y1336 was not a substrate for Src kinase in this paradigm (data not shown). Taken together, these results indicate that in HEK cells, SrcCA does not alter calpain-mediated cleavage of NR2B in this transfected cell paradigm nor does it readily mediate phosphorylation of Y1336 after NMDA receptor activation induced by glutamate and glycine. Thus in this system, Fyn (but not all SFKs) accelerates calpain-mediated NR2B cleavage.

Mutation of NR2B-Y1336 Blocks Fyn Mediated Facilitation of NR2B Cleavage - We examined the specific role of NR2B-Y1336 using the mutants NR2BY1336F and NR2BY1472F. Before agonist treatment, full-length NR2B immunoreactivity in cells transfected with NR2BY1336F or NR2BY1472F along with NR1/2A/SAP-102/FynY531F was comparable to that of NR2B wild-type (Fig. 6A). Following 30 min agonist treatment, the immunoreactivity of NR2BY1336F mutant decreased by 32%, a similar decrease to that noted with wild-type NR2B without FynY531F cotransfection (Fig. 6A, B; NR2Bwt/vector, 71 ± 8%; NR2BY1336F/FynY531F, 68 ± 1%, p = 0.59, n = 6 each), whereas the immunoreactivity of...
wild-type NR2B with FynY531F declined by 62% (Fig. 6A, B, NR2Bwt/FynY531F, 38 ± 3%, p = 0.023 vs NR2Bwt/vector and p = 0.036 vs NR2BY1336F/FynY531F, n = 6 each). In contrast, with FynY531F cotransfection, the immunoreactivity of NR2BWT decreased by 43%, a similar level to that of NR2B wild-type with FynY531F cotransfection (Fig. 6A, B, NR2BY1472F/FynY531F, 57 ± 2%; p = 0.45 vs NR2Bwt/FynY531F, p = 0.037 vs NR2Bwt/vector and p = 0.0022 vs NR2BY1336F/FynY531F, n = 6 each). Receptors made by expression of NR1/NR2A/NR2BY1336F, NR2BY1472F, or NR2B wild-type with FynY531F had similar NMDA receptor-mediated intracellular calcium responses (Fig 6D), indicating that the differences in the effect of FynY531F did not result from differential calcium responses to glutamatergic stimulation. Calpain-generated spectrin breakdown was similar in each condition (Fig. 6A, C). Thus, in HEK cells, prevention of Fyn-mediated phosphorylation of NR2B-Y1336 through mutation eliminates the facilitating effect of FynY531F on calpain-mediated NR2B cleavage.

Cellular Location of Fyn Facilitation of Calpain-mediated NR2B Cleavage in HEK Cells - Since activation of NMDA receptors leads to calpain-mediated NR2B cleavage in HEK cells in both the plasma membrane and intracellular compartments (16,24), we next investigated whether Fyn-mediated facilitation of NR2B cleavage occurred in a selective cellular compartment in HEK cells. Cells expressing NR1/NR2A/NR2B with or without FynY531F were treated with glutamate and glycine. Surface receptors were biotinylated, separated using avidin beads and detected by Western blotting using anti-N-terminal NR2B antibody. In each transfected condition (Fig. 7B, C), before agonist application, NR2B was found in both the cell surface fraction and the intracellular fraction. Actin was detected almost exclusively in the intracellular fraction confirming that biotinylation occurred only at the cell surface (Fig. 7B, C). Before agonist treatment, in both the surface and the intracellular fractions, the levels of immunoreactivity of NR2B in cells transfected with NR1/2B with or without FynY531F were similar (Fig. 7B, C). This suggests that basal Fyn-mediated phosphorylation of NR2BY1336 does not change the NR2B levels in each compartment in this system, including the subunit delivery to the cell surface. Following 30 min agonist treatment, the immunoreactivity of NR2B in the overall lysate declined compared to the corresponding control (0 min). (Fig. 7A, 35% decrease without FynY531F; 63% decrease in wild-type with FynY531F, n=6 each). In the cell surface fraction, agonist application decreased NR2B immunoreactivity by 33% in cells transfected with NR2B wild-type without FynY531F, by 62% in cells transfected with NR2B wild-type with FynY531F suggesting that NR2B cleavage is enhanced by FynY531F in the surface fraction (Fig. 7C; NR1/2B without FynY531F, 67 ± 2%; NR1/2B with FynY531F, 38 ± 3%; p = 0.0063 n=6 each). In the intracellular fraction, the decrease in levels of NR2B by agonist application was similar among wild-type NR2B with or without FynY531F (Fig. 7B; NR1/2B without FynY531F, Contr., 100 ± 3%, Glu., 41 ± 4%; NR1/2B with FynY531F, Contr., 100 ± 7%, Glu., 40 ± 2%; n = 6 each). Overall, the level of NR2B cleavage in the intracellular fraction in the absence of FynY531F was similar to the level cleavage with FynY531F in the surface fraction. This suggests that Fyn may relieve a tonic inhibition of cleavage of NR2B in the surface fraction. Overall, these results show that FynY531F mediated facilitation of NR2B cleavage in the cell surface fraction without significant effects on cleavage of intracellular receptors.

The Mechanism of Fyn-mediated Facilitation of NR2B Cleavage - Since cleavage of intracellular receptors was not enhanced by Fyn, we sought to better define the mechanism by which Fyn enhances calpain-generated cleavage of NR2B. In vitro, Fyn enhanced the speed of NR2B cleavage (Fig. 8A, B). This increase in the rate of cleavage was not noted in receptors formed from NR2BY1336F demonstrating that the mechanism of the effects of Fyn in vitro is
consistent with that observed in cell culture. Consequently, the effect of Fyn likely does not require processes observed only in situ (such as trafficking of NMDA receptors between cellular compartments). Additionally, FynY531F expression did not increase levels of NR2B on the cell surface either before or 30 min after agonist application in which calpain activity was blocked by its inhibitor, indicating that Fyn does not facilitate NR2B delivery to the cell membrane in this system (Fig. 8C, wt/vector, Contr., 100 ± 0.2%; Glu., 94 % ± 9, p = 0.27 vs Contr.; wt/FynY531F, Contr., 93 ± 11%, p = 0.44 vs Contr. of wt/vector; Glu., 93 ± 9%, p = 0.24 vs Contr. of wt/vector; n = 6 each). In addition, NR2BY1336 was phosphorylated to a similar degree in both cell surface and intracellular fractions (Fig. 8D, Surface, Contr., 100 ± 6%, Glu. 248 ± 24%; Intracellular, Control, 100 ± 8%, Glu., 210 ± 18%; n = 6 each). Thus, the selective enhancement of surface receptor cleavage by Fyn cannot simply reflect the distribution of phosphorylation. However, since calcium entry facilitates association of calpain with cell membranes including the plasma membrane (37,38), we investigated whether NMDA receptor activation translocated calpain I from the cytosol to the membrane area using biotinylation assays under non-denaturing conditions before and after agonist stimulation. This protocol should leave associations of calpain with membrane components intact and lead to retention of cell surface associated calpain in the biotinylated fraction. In transfected HEK cells, 100 µM glutamate treatment increased the calpain I immunoreactivity in the cell surface fraction 1.9-fold relative to levels before agonist stimulation, with no significant changes of calpain I levels in the intracellular fraction or the lysate (Fig. 8E, Surface, CalI3: 3300 ± 100, CalI3+Glu.: 6220 ± 380; Intracellular, CalI3: 11600 ± 4600, CalI3+Glu.: 12400 ± 140; Lysate, CalI3: 19300 ± 360, CalI3+Glu.: 20800 ± 400). Actin levels in the surface fraction were not detectably altered by 100 µM glutamate application for 30 min. Thus, overall the facilitation of calpain-mediated cleavage of NR2B appears to reflect an increased sensitivity of NR2B to calpain with phosphorylation at Y1336 and the translocation of activated calpain to the cell membrane area, creating a selective enhancement of cleavage in the cell surface fraction.

Cleavage of Full-length NR2B does not Decrease Extrasynaptic NMDA Receptor Function – Previously we demonstrated that calpain does not control the overall size of electrophysiological responses of NMDA receptors in DIV17 hippocampal neurons (19). However, in hippocampal neurons, extrasynaptic NMDA receptors preferentially contain NR2B (39) linked to SAP-102, not PSD-95. This makes extrasynaptic receptors the most likely selective physiologic target of neuronal calpain. We therefore investigated whether calpain-mediated cleavage of NR2B subunit alters extrasynaptic NMDA receptor function. To monitor pure extrasynaptic NMDA currents in cultures of hippocampal neurons, we selectively blocked synaptic NMDA receptors with an MK801-trapping technique that eliminates the contribution of synaptic receptors from the whole-cell response (39-41). In this paradigm though we also wished to examine whether activation of calpain would alter extrasynaptic currents, a goal requiring a control ensuring that the conditions needed to activate calpain did not unblock synaptic receptors. Since extrasynaptic receptors contain largely NR1/2B in hippocampal neurons, one can ensure that response reflect extrasynaptic receptors by their sensitivity to ifenprodil. Consistent with previous reports, blocking synaptic NMDA receptors with 50 µM bicineulline in conjunction with 10 µM MK-801 for 10 min reduced NMDA receptor current density by 69% from the control level of 107 ± 10 pA/pF (n = 12) to 33 ± 5 pA/pF (n = 18) (Fig 9A). The residual currents were almost completely abolished (5 ± 1 pA/pF, n = 5) by ifenprodil (10 µM), a selective antagonist of NR1/2B receptors, indicating that the whole-cell NMDA-evoked responses after bicineulline/MK801 pre-blocking reflected extrasynaptic currents consisting mainly of NR1/NR2B heteromers (Fig. 9A). With MK801/bicineulline pretreatment, neurons showed no apparent increase in
calpain activity based on spectrin cleavage and cleavage of NR2B (Fig 9B). However, if 100 µM glutamate was then applied to these neurons for 30 min, there was loss of full length NR2B, generation of a 115 kDa NR2B truncation and cleavage of spectrin, showing that isolated NR1/2B extrasynaptic receptors can activate calpain (Fig 9B). We then compared extrasynaptic NMDA receptor responses before and after calpain-mediated NR2B cleavage in bicuculline/MK801 pre-blocked neurons. As shown in Figure 9A, after application of 100 µM glutamate for 30 min in bicuculline/MK801 pre-blocked neurons, the NMDA receptor current density was 34 ± 4 pA/pF (n = 21), similar to the corresponding value obtained from bicuculline/MK801 pre-blocked neurons without glutamate treatment (33 ± 5 pA/pF; n = 18, p > 0.8). Inhibition of calpain activation with calpain inhibitor III significantly prevented the glutamate-induced decrease of full length of NR2B (Fig. 9B), but produced similar levels of extrasynaptic NMDA-evoked response (40 ± 5 pA/pF, n = 19, p > 0.3), compared with either glutamate treated or untreated neurons (Fig. 9A). Current evoked by NMDA after glutamate application for 30 min with or without calpain inhibitor III in bicuculline/MK801 pre-blocked neurons was completely blocked by ifenprodil (Fig. 9A), indicating no recovery of synaptic NMDA receptors following removal of bicuculline/MK801 during glutamate and calpain inhibitor III treatment (as these receptors typically are ifenprodil insensitive). This is consistent with previous studies showing that synaptic receptors remain blocked for this period after glutamate application (41). Thus, reducing levels of full length NR2B without a corresponding change in the current amplitude of response to NMDA indicates that calpain-mediated loss of full-length NR2B does not cause a functional decrease in extrasynaptic NMDA receptors.

**Calpain-Truncated NR2B-Containing NMDA Receptors are Functional in HEK Cells** - We then attempted to confirm that receptors containing calpain-truncated NR2B remain active. Based on the expected molecular weight of the truncated form (roughly 1030 amino acids) (16) generated by calpain in neurons, we produced a construct leading to NR2B truncated at amino acid 1036 (NR2Bdel1036) by insertion of two consecutive stop codons and then examined its functional properties. In HEK cells expressing NR1/NR2Bdel1036, western blots of biotinylated samples demonstrated that the truncated NR2B subunit was expressed on the cell surface (Fig. 9C). In addition, NMDA receptors incorporating NR2Bdel1036 produced intracellular calcium transients similar to wild type receptors when stimulated with agonists (data not shown). Electrophysiologically, brief (2 s) application of 100 µM NMDA activated both wild-type and NR2Bdel1036 containing receptors with no significant difference in current density (current amplitude normalized to cell capacitance; wild-type: 90 ± 15 pA/pF, n = 24; NR1/NR2Bdel1036: 103 ± 13.3 pA/pF, n = 35). In addition, the percentage current desensitization of NR1/NR2Bdel1036 was statistically indistinguishable from those found in cells expressing wild-type receptors (Fig. 9D). This result indicates that calpain truncated NR2B-containing NMDA receptors are functional in HEK cells. These data also demonstrate that Fyn phosphorylation of NR2B facilitates the generation of truncated receptors that function similarly to full-length receptors but lack the domains necessary for intracellular signal transduction, which may play critical roles in synaptic plasticity or excitotoxicity.

**DISCUSSION**

In the present study, we have demonstrated that the tyrosine kinase Fyn controls the ability of the NR2B subunit to be cleaved by calpain in neurons and in model expression systems. In neurons, SFK inhibitors and siRNA specific for Fyn slow calpain-mediated cleavage of NR2B but do not alter cleavage of spectrin. In HEK cells, calpain-mediated cleavage is accelerated by constitutively active Fyn, but not Src. Calpain-mediated cleavage is enhanced in association with phosphorylation of NR2BY1336 but not NR2B-Y1472, and site-directed mutagenesis demonstrates that removal of Y1336 (but not Y1472) removes...
Fyn, calpain and NR2B

the ability of Fyn to potentiate NR2B cleavage by calpain. These data demonstrate that Fyn enhances calpain-mediated cleavage of NR2B in multiple experimental conditions through a mechanism involving direct phosphorylation of NR2B.

The interactions of Fyn, NR2B and calpain are also controlled by the specific MAGUK protein involved in NR2B binding. Both SAP-102 and PSD-95 enhance phosphorylation of NR2B-Y1336 by Fyn. However, as shown previously, PSD-95 blocks the ability of calpain to cleave NR2 subunits (24), and phosphorylation by Fyn was unable to override this effect. This suggests that in neurons the NR2B cleaved by calpain is most likely bound to SAP-102 and phosphorylated by Fyn. Based on the requirement for SAP-102 (compared with PSD-95) and the preference for cleavage of NR2B rather than NR2A, most calpain cleaved NMDA receptors are likely to be extrasynaptic NR1/2B receptors. In addition, our data show that such receptors (both extrasynaptic receptors in neurons and truncated NR1/2B in heterologous cells) are predicted to have electrophysiological features similar to full length receptors. This shows that the primary effect of calpain in our system is not simply degradative, but may create receptors with novel properties based on the dissociation of channel activity from downstream messenger systems, such as p38 MAP kinase dephosphorylation and PI3 kinase activation. Such receptors could then play crucial roles in the various roles of NMDA receptors, including excitotoxicity and synaptic modification. The mechanism by which Fyn controls cleavage of NR2B may have several different components. Fyn accelerated the cleavage in vitro of recombinant receptors in a manner that depended on NR2B-Y1336, suggesting that Fyn directly enhances the substrate characteristics of the C-terminus of NR2B. This has been noted previously for NR2A and NR2B in brain homogenates, and in fusion proteins of NR2B from 1269-1482 (35), suggesting that the effect of Fyn is mediated entirely within these amino acids and matching the dependence on NR2B-Y1336 demonstrated here. These data suggest that at least some aspect of the mechanism of the effects of Fyn is a direct biochemical effect on the substrate properties of the C terminal region of NR2B.

However, in HEK cells the subcellular localization of the enhancement of calpain-mediated cleavage suggests other aspects to the mechanistic effects of Fyn. Even though calpain can cleave NR2B within intracellular compartments and Fyn can phosphorylate NR2B-Y1336 in intracellular compartments, Fyn did not enhance calpain-mediated cleavage in these compartments. This is consistent with the localization of NR2B in neurons, where most NR2B is located on the cell surface in hippocampal cultures (16), but suggests that factors beyond biochemical aspects contribute to the effects of Fyn on calpain-mediated cleavage of NR2B. One factor could be increased trafficking of NR2B to the cell surface after activation of Fyn. However, the presence of constitutively active Fyn (with resultant baseline phosphorylation of Y1336) did not increase levels of NR2B on the cell surface, nor did agonist treatment of receptors (with Fyn activation) during calpain blockade alter surface NR2B levels. Thus, increased trafficking of NR2B to the cell surface cannot explain the selective enhancement of cleavage by Fyn in this compartment. Instead, calpain, previously reported to associate with membranes after activation (37,38), increased in the cell surface fraction under non-denaturing conditions (Fig. 8E), suggesting that targeting of calpain to the plasma membrane mediates the selective enhancement of cleavage in the cell surface fraction. The regulatory subunit of calpain has been associated with synaptic membranes in proteomic experiments (42). These results suggest that the biochemical enhancement of NR2B degradation by Fyn in conjunction with calpain transport to the plasma membrane provide the mechanism for selective enhancement of cleavage by Fyn in the cell surface fraction. However, calpain also can associate with internal membranes after rises in intracellular calcium, suggesting that the translocation of calpain to the plasma
membrane may only be a partial explanation for the compartmentalized effect of Fyn. The level of cleavage of NR2B in intracellular compartments was essentially equal to that observed with enhancement by Fyn in the surface fraction, suggesting that unidentified plasma membrane components tonically inhibit cleavage of NR2B. It is conceivable that such components (structural features of the attachment of NR2B to MAGUK proteins or plasma membrane lipids, association with RACK1 or related proteins) selectively inhibit calpain-mediated NR2B cleavage in a manner that is relieved by phosphorylation by Fyn.

Fyn modulates NMDA receptors in several ways (33,43-46). Although Fyn has not clearly been shown to alter channel function directly, Fyn enhances transport of NR2 subunits to the cell surface and into the synapse under different conditions and blocks internalization of NR2B containing receptors (47). However these effects are most likely mediated by Y1472 based on site directed mutagenesis (23,45,46). The control of calpain-mediated cleavage appears to reflect events occurring with phosphorylation of Y1336, a site that is phosphorylated in cellular systems to a slightly lower degree than Y1472. This site also controls activation of PI3 kinase and dephosphorylation of p38 MAP kinase, potential protective mechanisms in neurons (22). This suggests that the events occurring with Y1336 phosphorylation provide a set of responses distinct from the role of Fyn in organizing NR2B localization at the synapse through receptor trafficking and internalization.

The effect of Fyn here does not entirely match in vitro results examining calpain-mediated cleavage of NR2 subunits. While Fyn accelerated cleavage of NR2B subunits in vitro, the same effect is seen on NR2A. However, the selective binding of NR2A to PSD-95 in synapses limits its ability to be cleaved in neurons (24). Src blocks calpain-mediated cleavage in vitro (through an unknown mechanism), but constitutively active Src did not lead to phosphorylation at Y1336 in situ, nor did it alter the speed of cleavage of NR2B by calpain. This result agrees with the observation that among MAGUK proteins, only PSD-95 binds Src (48). Our data illustrate that the interaction of MAGUK proteins and SFK regulate the cleavage of NR2 subunits by calpain in living cells, and that when calpain mediated cleavage of NR2B is examined in situ, only Fyn alters this process.

Fyn significantly contributes to tyrosine phosphorylation of NMDA receptors and Fyn mutant mice show defects in NMDA receptor-dependent LTP (43). However, NMDA receptor activation itself has not been shown to stimulate Fyn activity. In the present study, phosphorylation of NR2B-Y1336 increased with NMDA receptor stimulation in cultured hippocampal neurons or HEK cells expressing NR2B containing NMDA receptors. These effects were blocked with MK801 and suggest that NMDA receptors could directly activate Fyn. However, NMDA receptor stimulation did not enhance phosphorylation of NR2B-Y1472, suggesting that NMDA receptor stimulation may instead direct the activity of Fyn to a different site on the NMDA receptor. Selective Fyn-mediated phosphorylation of Y1336 is also seen in neurons treated with ethanol, in which it is controlled by dissociation of RACK1 from NR2B (33). Nevertheless, the present results indicate that the NR2B/Fyn/calpain interactions may act as part of a Fyn kinase cascade, which in turn regulates NMDA receptor features through promoting calpain-mediated cleavage of NR2B subunits. Further experiments are required to investigate the mechanisms by which NMDA receptor activation is coupled to Fyn-mediated phosphorylation of NR2B-Y1336 and calpain-mediated cleavage of NR2B in neuronal pathophysiology.

In summary, the present study provides a model for understanding the control and selectivity of neuronal calpain for selected proteins in synaptic and extrasynaptic membranes. As calpain cleaved receptors dissociated from intracellular signal transduction elements remain on the cell surface and are active similarly to those of wild-type receptors, the present data demonstrate a new manner in which Fyn may contribute to enhancement of synaptic
plasticity or excitotoxicity in neuronal systems.

REFERENCES

1. Lynch, D. R., and Guttmann, R. P. (2002) J Pharmacol Exp Ther 300, 717-723.
2. Lynch, D. R., and Guttmann, R. P. (2001) Current Drug Targets 2, 215-231.
3. Mayer, M. L., and Westbrook, G. L. (1987) Prog Neurobiol 28, 197-276.
4. Collingridge, G. L., and Bliss, T. V. (1995) Trends Neurosci 18, 54-56.
5. Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., and Seeburg, P. H. (1992) Science 256, 1217-1221.
6. Kutsuwada, T., Kashiwabuchi, N., Mori, H., Sakimura, K., Kushiya, E., Araki, N., Meguro, H., Masaki, H., Kumanishi, T., and et al. (1992) Nature 358, 36-41.
7. Meguro, H., Mori, H., Araki, K., Kushiya, E., Kutsuwada, T., Yamazaki, M., Kumanishi, T., Arakawa, M., Sakimura, K., and Mishima, M. (1992) Nature 357, 70-74.
8. Ishii, T., Moriyoshi, K., Sugihara, H., Sakurada, K., Kadotani, H., Yokoi, M., Akazawa, C., Shige moto, R., Mizuno, N., Masu, M., and et al. (1993) J Biol Chem 268, 2836-2843.
9. Watanabe, M., Inoue, Y., Sakimura, K., and Mishina, M. (1992) NeuroReport 3, 1138-1140.
10. Kutsuwada, T., Sakimura, K., Manabe, T., Takayama, C., Katakura, N., Kushiya, E., Natsune, R., Watanabe, M., Inoue, Y., Yagi, T., Aizawa, S., Arakawa, M., Takahashi, T., Nakamura, Y., Mori, H., and Mishina, M. (1996) Neuron 16, 333-344.
11. Ebralidze, A. K., Rossi, D. J., Tonegawa, S., and Slater, N. T. (1996) J Neurosci 16, 5014-5025.
12. Kadotani, H., Hirano, T., Masugi, M., Nakamura, K., Nakao, K., Katsuki, M., and Nakanishi, S. (1996) J Neurosci 16, 7859-7867.
13. Sprengel, R., Suchanek, B., Amico, C., Brusa, R., Burnashev, N., Rozov, A., Hvalby, O., Jensen, V., Paulsen, O., Andersen, P., J. K. J., Thompson, R. F., Sun, W., Webster, L. C., Grant, S. G., Eilers, J., Konnerth, A., Li, J., McNamara, J. O., and Seeburg, P. H. (1998) Cell 92, 279-289.
14. Guttmann, R. P., Baker, D. L., Seifert, K. S., Cohen, A., Coulter, D. A., and Lynch, D. R. (2001) J Neurochem 78, 1083-1093.
15. Guttmann, R. P., Sokol, S., Baker, D. L., Simpkins, K. L., Dong, Y., and Lynch, D. R. (2002) J Pharmacol Exp Ther 302, 1023-1030.
16. Simpkins, K. L., Guttmann, R. P., Dong, Y., Chen, Z., Sokol, S., Neumar, R. W., and Lynch, D. R. (2003) J Neurosci 23, 11322-11331.
17. Araujo, I., Xapelli, S., Gil, J., Mohapel, P., Petersen, A., Pinheiro, P. S., Malva, J. O., Bahr, B., Brundin, P., and Carvalho, C. M. (2005) NeuroReport 16, 393-396.
18. Wu, H. Y., Yuen, E. Y., Lu, Y. F., Matsushima, M., Matsui, H., Yan, Z., and Tomizawa, K. (2005) J Biol Chem 280, 21588-21593.
19. Dong, Y., Wu, H. Y., Hsu, F. C., Coulter, D. A., and Lynch, D. R. (2006) J Neurochem 99:206-17.
20. Moon, I. S., Apperson, M. L., and Kennedy, M. B. (1994) Proc Natl Acad Sci U S A 91, 3954-3958.
21. Gurd, J. W., and Bissonon, N. (1997) J Neurochem 69, 623-630.
22. Waxman, E. A., and Lynch, D. R. (2005) J Biol Chem 280, 29322-29333.
23. Nakazawa, T., Komai, S., Tezuka, T., Hisatsune, C., Umemori, H., Semba, K., Mishina, M., Manabe, T., and Yamamoto, T. (2001) J Biol Chem 276, 693-699.
24. Dong, Y. N., Waxman, E. A., and Lynch, D. R. (2004) J Neurosci 24, 11035-11045.
25. Grant, E. R., Basckai, B. J., Gallagher, M. J., Kendrick, S. L., Pritchett, D. B., Kricka, L., Pleasure, D. P., and Lynch, D. R. (1997) J Biol Chem 272, 647-656.
26. Lynch, D. R., Shim, S. S., Seifert, K. M., Kurapathi, S., Mutel, V., Gallagher, M. J., and Guttmann, R. P. (2001) Eur J Pharmacol 416, 185-195.
27. Sims, K. D., Straff, D. J., and Robinson, M. B. (2000) *J Biol Chem.* 275, 5228-5237.
28. Anegawa, N. J., Lynch, D. R., Verdoorn, T. A., and Pritchett, D. B. (1995) *Journal of Neurochemistry* 64, 2004-2012
29. Yang, M., and Leonard, J. P. (2001) *J Neurochem.* 77, 580-588.
30. Cheung, H. H., and Gurd, J. W. (2001) *J Neurochem.* 78, 524-534
31. Zheng, F., Gingrich, M. B., Traynelis, S. F., and Conn, P. J. (1998) *Nat Neurosci* 1, 185-191
32. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., and Connely, P. A. (1996) *J Biol Chem* 271, 695-701
33. Yaka, R., Phamluong, K., and Ron, D. (2003) *J Neurosci* 23, 3623-3632
34. Sala, C., and Sheng, M. (1999) *Proc Natl Acad Sci U S A* 96, 335-337
35. Rong, Y., Lu, X., Bernard, A., Khrestchatisky, M., and Baudry, M. (2001) *J Neurochem* 79, 382-390
36. Sui, G., Soohoo, C., Affar, e. B., Gay, F., Shi, Y., Forrester, W. C., and Shi, Y. (2002) *Proc Natl Acad Sci U S A* 99, 5515-5520
37. Pontremoli, S., Melloni, E., Salamino, F., Patrone, M., Michetti, M., and Horecker, B. L. (1989) *Biochem Biophys Res Commun* 160, 737-743
38. Ariyoshi, H., Shiba, E., Sakon, M., Kambayashi, J., Yoshida, K., Kawashima, S., and Mori, T. (1993) *Biochem Mol Biol Int* 30, 63-72
39. Tovar, K. R., and Westbrook, G. L. (1999) *J Neurosci.* 19, 4180-4188.
40. Tovar, K. R., and Westbrook, G. L. (2002) *Neuron* 34, 255-264.
41. Hardingham, G. E., Fukunaga, Y., and Bading, H. (2002) *Nat Neurosci.* 5, 405-414.
42. Husi, H., Ward, M. A., Choudhary, J. S., Blackstock, W. P., and Grant, S. G. N. (2000) *Nat Neurosci* 3, 661-669
43. Grant, S. G., O'Dell, T. J., Karl, K. A., Stein, P. L., Soriano, P., and Kandel, E. R. (1992) *Science* 258, 1903-1910
44. Miyakawa, T., Yagi, T., Kitazawa, H., Yasuda, M., Kawai, N., Tsuboi, K., and Niki, H. (1997) *Science* 278, 698-701
45. Lavezzari, G., McCallum, J., Lee, R., and Roche, K. W. (2003) *Neuropharmacology* 45, 729-737
46. Prybylowski, K., Chang, K., Sans, N., Kan, L. L., Vicini, S., and Wenthold, R. J. (2005) *Neuron* 47, 845-857
47. Dunah, A. W., Siriani, A. C., Fienberg, A. A., Bastia, E., Schwarzschild, M. A., and Standaert, D. G. (2004) *Mol Pharmacol.* 65, 121-129.
48. Kalia, L. V., and Salter, M. W. (2003) *Neuropharmacology* 45, 720-728

**FOOTNOTES**

We would like to thank Margie Maronski for hippocampal neuron preparation. This work was supported by funds from National Institutes of Health Grant NS45986, the Trisomy 21 program and Mental Retardation Research Center of the Children’s Hospital of Philadelphia (to DRL) and American Heart Association Grant 0625390U (to HYW).

The abbreviations used are: NMDA, N-methyl-D-aspartate; SFK, Src family kinase; MK-801, dizocilpine; HEK, Human embryonic kidney; PSD-95, post synaptic density protein 95; MAGUK, membrane-associated guanylate kinases; CalII3, Calpain Inhibitor III (MDL 28170; Z-Val-Phe-CHO); PP2, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine; NR2Bdel1036, NR2B truncated at 1036 amino acid; RACK1, receptor for activated protein kinase C 1.

**FIGURE LEGENDS**
Figure 1. Prevention of calpain-mediated NR2B cleavage by inhibition of Src family kinase (SFK) activity in cultures of hippocampal neurons. A, Cultures of hippocampal neurons (15-21 DIV) either untreated (0 min) or treated with 100 µM glutamate and 100 µM glycine for 30 min in presence of PP2 (10 µM) or DMSO (PP2-) (control). Neurons were harvested 30 min after addition of agonists, and samples were subjected to SDS-PAGE and Western blot analysis with an N-terminal NR2B antibody (upper panel) and AB38 (recognizing a calpain-generated spectrin breakdown product) (lower panel). The lower band in the upper panel is a calpain-mediated NR2B breakdown product (16). B and C, Bar graphs demonstrate the levels of full-length NR2B and NR2B-derived breakdown after indicated treatments. The expression level of each control was normalized to 100% (based on NR2B full length), and the levels of each band after various treatments were calculated as the percentages of corresponding control values. D, Bar graph shows elevated levels of the calpain-generated spectrin breakdown after indicated treatments. Data are means ± SEM from six experiments. * p < 0.05, ** p < 0.001, ANOVA. (Glu. in this figure and all other figures represents treatment with 100 µM glutamate and 100 µM glycine).

Figure 2. NR2B is phosphorylated at Y1336, and inhibition of Y1336 phosphorylation prevents calpain-mediated NR2B cleavage in cultures of hippocampal neurons. A, Cultures of hippocampal neurons (15-21 DIV) were treated with 100 µM glutamate and 100 µM glycine for various amounts of time in the presence of 10 µM PP2 (PP2 (+)) or DMSO control (PP2 (-)). Neurons were harvested at each indicated time after addition of agonist, and samples were subjected to SDS-PAGE and Western blot analysis with an NR2B phospho-specific anti-Y1336 antibody (upper panel), an N-terminal NR2B antibody (middle panel) or an antibody to phosphorylated NR2B-Y1472. B, C and D, Quantification of immunoreactivity of Y1336 phosphorylation, full-length NR2B, and the 115kD NR2B-derived breakdown product for the indicated length of time in the presence or absence of PP2 during agonist stimulation. E, NR2B-Y1336 was a calpain substrate and phosphorylation of NR2B-Y1336 was blocked by MK-801 in cultured neurons. Neurons were treated with or without glutamate (100 µM) and glycine (100 µM) for 30 min in presence or absence of calpain inhibitor III (CalI3, 10 µM) or MK-801 (10 µM), and equal amounts of protein were then analyzed by Western blot using an antibody to NR2B-Y1336. Data are means ± SEM from six experiments. * p < 0.05, ** p < 0.001, ANOVA.

Figure 3. Prevention of calpain-mediated NR2B cleavage by targeting Fyn with siRNA in neurons. A, Knockdown of endogenous Fyn protein by siRNA in HEK cells. Lysates from mock (mock)- and Fyn RNAi-transfected cells (siRNA) were analyzed by Western blotting 96 hrs after transfection. Mock, an siRNA construct designed to have no effect on Fyn expression. B and C, Western blot analysis of Fyn protein expression and NR2B Y1336 phosphorylation in rat hippocampal neurons transfected with mock or siRNA. Neurons were transfected at 10-11 DIV and knockdown of Fyn protein expression was assessed 96 hrs after siRNA nucleofection (15-16 DIV). Phosphorylation of NR2B Y1336 (C) was compared between mock and siRNA transfected neurons with or without agonist stimulation (glutamate 100 µM and glycine 100 µM for 30 min). D, Representative immunoblots indicate protein levels of NR2B, spectrin breakdown, and NR1 during NMDA receptor activation in non-transfected, Fyn siRNA-transfected and mock-transfected hippocampal neurons. E, and F, Quantification of relative expression full-length NR2B, and calpain-generated NR2B-derived breakdown product from D. Data are mean ± SEM from 5 or more experiments. * p < 0.05, ** p < 0.001, ANOVA.

Figure 4. Facilitation of calpain-mediated NR2B cleavage by Fyn Y531F, which phosphorylates NR2B-Y1336 in HEK 293 cells. A, Coexpression of either PSD-95 or SAP-102 with FynY531F and NR2B promoted phosphorylation of NR2B-Y1336 (upper panel) compared with vector control. PSD-95 and SAP-102 cotransfection with FynY531F did not increase levels of NR2B (middle panel) and
actin (lower panel). B, Representative immunoblots after designated treatments (sham, Glu/Gly, CalI3) detected by NR2B antibody, phospho-Y1336 specific antibody, AB38 and actin antibody. C, D and E, Quantification of relative levels of full-length NR2B, Y1336 phosphorylation, and spectrin breakdown from results of B. A greater decrease in full-length NR2B was observed 30 min after glutamate and glycine treatment in cells coexpressing NR1/2A/2B/SAP-102 with FynY531F compared to that from cells not transfected with FynY531F. In both types of transfection, calpain-generated spectrin products increased to a similar extent. No change in actin signal was detected. Data are mean ± SEM from 5 or more experiments. In panel D, data are expressed as absolute values of signal intensity determined by NIH image. * p < 0.05, ** p < 0.001, ANOVA.

Figure 5. The effect of PSD95 on Fyn-mediated facilitation of NR2B cleavage and the role of Src in calpain-mediated cleavage of NR2B. A, B and C, HEK cells were transfected with NR1/2A/2B/PSD-95 and Fyn and treated with 100 µM glutamate and 100 µM glycine in the presence or absence of calpain inhibitor III. Cells were harvested 30 min after agonist application, and samples were subjected to 8% SDS-PAGE and Western blot analysis with an NR2B phospho-specific anti-Y1336 antibody (A), an N-terminal NR2B antibody (B), and AB38 antibody (C). Even with FynY531F phosphorylation of NR2B-Y1336 after NMDA receptor activation, PSD-95 coexpression prevented NR2B cleavage by calpain. D, Representative blots of NR2B, spectrin breakdown and actin, as well as quantitative levels of NR2B from HEK cells expressing constitutively active Src or a control vector with NR1/2A/2B/SAP-102. SrcCA did not prevent nor facilitate calpain-mediated cleavage of NR2B at 30 min after NMDA receptor activation in HEK cells. Data are representative of four independent experiments and are shown as mean ± SEM.

Figure 6. Blockade of FynY531F-induced facilitation of NR2B cleavage by mutation of NR2BY1336, but not Y1472. A, Representative immunoblots with NR2B antibody, AB38 and anti-actin antibody. HEK 293 cells were transfected with combinations of expression plasmids for NR2B wild-type or NR2B mutants (Y1336F, Y1472F), and NR1/2A/SAP-102 with or without FynY531F. Twenty-four hrs after transfection, cells were treated with glutamate and glycine for 30 min, and lysates were subjected to immunoblotting with the anti-NR2B, AB38 and actin antibodies. B and C, Quantification of the relative levels of full-length NR2B and calpain-generated spectrin product. Absolute integrated OD values are displayed. D, NMDA-mediated intracellular calcium responses in transfected HEK293 cells containing wild-type or mutant NR2B. The cells were loaded with 5 µM fura-2 and then stimulated with 100 µM glutamate and 100 µM glycine. Peak calcium concentrations (nM) were typically observed within 30 sec. Data from 20-30 individual cells were collected per experiment, and ensemble averages were calculated. n = 10. Data are means ± SEM.

Figure 7. Cellular location of the effect of Fyn on calpain-mediated NR2B cleavage in HEK cells. A, B and C, representative blots and histogram showing NR2B levels in different cellular compartment in cells transfected with NR1/2B with or without FynY531F before (control) and 30 min after agonist application. Quantification of the NR2B levels by biotinylation showed that NR2B levels decreased to a greater degree in the lysate (A) and the surface fraction (C) in cells coexpressing FynY531F than those expressing a vector control. In the intracellular fraction (B), quantification showed that the levels of NR2B with or without FynY531F decreased to a similar extent after agonist application. Biotinylation data were obtained from six independent experiments performed in triplicate. Error bars indicate SEM.

Figure 8. Mechanistic studies on the facilitation of calpain-mediated cleavage of NR2B by Fyn. A, Representative blots showing cleavage of NR2B in vitro by recombinant calpain I with or without active Fyn protein pretreatment. Homogenates from HEK293 cells transfected with wild-type NR2B or NR2B mutant Y1336F and NR1 were pretreated with or without 100 ng active Fyn protein for 40
min at 30°C. After pretreatment, samples were then treated with 2 unit/ml recombinant calpain I for 2 min. B, Quantitative data obtained from 5 independent experiments show that Fyn treatment accelerates the cleavage of wild-type NR2B but not NR2BY1336F. C, Representative blots and their quantification showed similar levels of NR2B immunoreactivity in the surface fractions of HEK293 cells transfected with NR1/2A/2B with and without FynY531F and with or without agonist stimulation. D, Representative blots and quantification of NR2B-pY1336 immunoreactivity in surface and intracellular fractions from cells transfected with NR1/2A/2B/SAP-102/FynY531F in control conditions and following 30 min agonist treatment. For C. and D., Calpain inhibitor III (CalI3) was included during agonist treatment to avoid calpain-induced degradation of NR2B. All biotinylated samples were obtained from six independent experiments. Error bars indicate SEM. E, Representative blots and histogram showing levels of calpain I immunoreactivity associated with different cellular compartments (under non-denaturing conditions) in cells transfected with NR1/2A/2B/SAP-102 and FynY531F following agonist stimulation for 30 min. All biotinylated samples were obtained from 6 independent experiments. Error bars indicate SEM. Sur=surface, Intr=intracellular, Lys =lysate.

Figure 9. Decreasing full-length NR2B does not decrease extrasynaptic NMDA receptor function and calpain-truncated NR2B containing receptors are functional in HEK cells. A, Extrasynaptic NMDA receptor-mediated currents in hippocampal culture neurons were isolated by blocking synaptic NMDA receptor with 50 μM bicuculline and 10 μM MK801 pre-treatment. NMDA receptor current density was reduced. NMDA-evoked currents in glutamate-treated, with or without calpain inhibitor III in bicuculline/MK801 pre-blocked neurons were both almost completely blocked by ifenprodil (10 μM; See Methods for details), consistent with extrasynaptic receptors being the only population activated by glutamate after bicuculline/MK801 blockade. In addition ifenprodil did not completely block the NMDA-evoked current in control (no bicuculline/MK801) neurons indicating the existence of receptors of subunit composition other than NR1/NR2B (presumptively NR1/2A/2B) in control neurons. B, MK801/bicuculline pre-blocked hippocampal neurons (17-21 DIV) either untreated or treated with 100 μM glutamate and 100 μM glycine for 30 min. Neurons were harvested 30 min after addition of agonists, and samples were subjected to SDS-PAGE and Western blot analysis with an N-terminal NR2B antibody (upper panel), AB38 (middle panel) and actin (lower panel). C, Representative blots from biotinylation assay showing that like wild-type NR2B, NR2Bdel1036 expressed in the cell surface when cotransfected with NR1. D, NMDA receptor current properties were not different between NR1/ NR2Bdel1036 and NR1/NR2Bwt transfected HEK-293 cells. There were no differences in current density (left), or percentage of current desensitization (right) between both groups of transfected cells. ** p < 0.001, ANOVA
Figure 1

A

| PP2 (-) | PP2 (+) |
|---------|---------|
| Contr.  | Glu.    |
| Contr.  | Glu.    |

NR2B
- 180 kDa
- 115 kDa
AB38
- 150 kDa

B

NR2B immunoreactivity (% of full-length under control conditions)

C

NR2B Breakdown Product (% vs full-length under control conditions)

D

AB38 immunoreactivity (% of control conditions)
**Figure 2**

**A**

NR2B-pY1336 immunoreactivity (% of intensity at 0 min) for PP2 (-) and PP2 (+) conditions.

**B**

NR2B-pY1336 immunoreactivity (% of intensity at 0 min) over time (min) for PP2 (-) and PP2 (+) conditions.

**C**

NR2B full-length immunoreactivity (% of intensity at 0 min) over time (min) for PP2 (-) and PP2 (+) conditions.

**D**

NR2B breakdown product (% vs full length at 0 min) over time (min) for PP2 (-) and PP2 (+) conditions.

**E**

NR2B-pY1336 immunoreactivity (% of control) for different conditions: Contr., Glu., CalB3+Glu., MK801+Glu.
Figure 3

A (HEK293)  B (Neuron)  C (Neuron)

D

E  F
Figure 4

A

Vector/FynY531F
SAP102/FynY531F
PSD95/FynY531F

pY1336
NR2B
Actin

B

|          | Vector/SAP102 | FynY531F/SAP102 |
|----------|---------------|-----------------|
| CalI3    | -             | -               |
| Glu.     | -             | +               |
| NR2B     | +             | +               |
| pY1336   |               | -               |
| AB38     |               | -               |

C

- Contr.
- Glu.
- CalI3+Glu.

D

NR2B immunoreactivity (% of intensity at 0 min)

- vector
- FynY531F

E

AB38 immunoreactivity (% of control)

- vector
- FynY531F
Figure 5

A

NR2B-pY1336 immunoreactivity (% vs Contr.)

Contr. Glu. Glu.+CalI3

B

NR2B immunoreactivity (% vs Contr.)

Contr. Glu. Glu.+CalI3

C

AB38 immunoreactivity (% vs Contr.)

Contr. Glu. Glu.+CalI3

D

NR2B immunoreactivity (% vs Contr.)

Contr. Glu. Contr. Glu (min)

AB38, Actin

Contributors: Glu., Glu.+CalI3

SsrcA, vector
Figure 6

A

| Glu. | wt/vector | wt/FynY531F | Y1336F/FynY531F | Y1472F/FynY531F |
|------|-----------|-------------|-----------------|-----------------|
| -    | +         | -           | +               | -               |

NR2B

AB38

Actin

NR2B immunoreactivity (% of intensity at 0 min)

Contr.  | Glu.
---|---

Y2F/FynY531F

Y1336F/FynY531F

Y1472F/FynY531F

AB38 immunoreactivity (intensity)

Contr.  | Glu.
---|---

Y2F/FynY531F

Y1336F/FynY531F

Y1472F/FynY531F

change in intracellular Ca^{2+} (nM)

Contr.  | Glu.
---|---

Y2F/FynY531F

Y1336F/FynY531F

Y1472F/FynY531F
Figure 7

A  Lysate

|          | Contr. | Glu. | Contr. | Glu. |
|----------|--------|------|--------|------|
| wt/vector|        |      |        |      |
| wt/FynY531F|     |      |        |      |

NR2B
NR1
Actin

B  Intracellular

|          | Contr. | Glu. | Contr. | Glu. |
|----------|--------|------|--------|------|
| wt/vector|        |      |        |      |
| wt/FynY531F|     |      |        |      |

NR2B
NR1
Actin

C  Surface

|          | Contr. | Glu. | Contr. | Glu. |
|----------|--------|------|--------|------|
| wt/vector|        |      |        |      |
| wt/FynY531F|     |      |        |      |

NR2B
NR1
Actin
Figure 8

A

Fyn (-)  
Wt  Y1336F  
0  2  0  2  
(min)

Fyn (+)  
Wt  Y1336F  
0  2  0  2  
→ 180 kDa 
→ 115 kDa

B

Full-length NR2B (% vs 0 min)

|           | 0 min | 2 min |
|-----------|-------|-------|
| Wt        | 100   | 100   |
| Y1336F    | 100   | 100   |

C

Surface fraction of NR2B (% vs wt/vector)

D

NR2B-pY1336 immunoreactivity (% vs contr.)

E

Calpain I Immunoreactivity (intensity)

CalI3  CalI3+Glu.

Fyn (-)                 Fyn (+)
Wt  Y1336F  Wt  Y1336F
0  2  0  2  0  2  0  2

Sur.  Intr.  Lys.
Calpain I Actin

CalI3  CalI3+Glu.

Sur.  Intr.  Lys.
Figure 9

A. Hippocampal neurons

Control  |  Bicu + MK801  |  Bicu + MK801 + Glu  |  Bicu + MK801 + Glu + Cali3

100 μM NMDA + 10 μM glycine + ifenprodil

NMDAR current density (pA/pF)

B, C. Western blot analysis

NR2B-wt  |  NR2B-del-1036

AB38  |  Actin

150 kDa  |  115 kDa  |  180 kDa  |  42 kDa

Bicu/MK801  |  Bicu/MK801 + Glu  |  Bicu/MK801 + Cali3

D. NMDA current density

NR2B-wt  |  NR2B-del-1036

100 μM NMDA + 10 μM Glycine

NMDA current density (pA/pF)

% current desensitization
FYNT-mediated phosphorylation of NR2B TYR-1336 controls calpain-mediated NR2B cleavage in neuron and heterologous systems
Hai-Yan Wu, Fu-Chun Hsu, Amy J. Gleichman, Isabelle Baconguis, Douglas A. Coulter and David R. Lynch

J. Biol. Chem. published online May 25, 2007

Access the most updated version of this article at doi: 10.1074/jbc.M700624200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts